About Sutro Biopharma

Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next generation cancer and autoimmune therapeutics — Antibody Conjugates, Bispecific Antibodies and Cytokine derivatives. Unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell.

Learn More

Technology

Our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency.

Learn More

Pipeline

Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies, and antibody-based therapeutics targeting immuno-oncology pathways.

Learn More

Recent News

10Oct

World Anti-Body Drug Conjugate (ADC) 2019 – Process Development and Scale Up for Site-Specific Bioconjugate Conjugation and Purification Poster

World Anti-Body Drug Conjugate (ADC) 2019  Process Development and Scale Up for Site-Specific Bioconjugate Conjugation and Purification Please Click the Link, World ADC.. Read More →
08Oct

Sutro Biopharma to Receive Milestone Payment for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors

Sutro Biopharma to Receive Milestone Payment for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors – Merck KGaA, Darmstadt, Germany Designates Undisclosed Bispecific.. Read More →

Careers

At Sutro, collaboration drives how we achieve results. By putting the goals of the Company first, we aim to make a difference both as individuals and as part of a team.

Learn More